CliffBio
small molecule

LAMPIT

NIFURTIMOX

Loss of exclusivityAugust 2027FDA regulatory exclusivity expiry
CompanyBayer Healthcare →See this company's full patent-cliff portfolio

Drug detail

Brand nameLAMPIT
Active ingredientNIFURTIMOX
Strength30MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2020
Marketing statusRX

Regulatory exclusivity

CodeExpires
ODE-319August 2027

More from Bayer Healthcare

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

LAMPIT patent cliff — loss of exclusivity August 2027 | CliffBio